Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

@article{Braun2007DifferencesIT,
  title={Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.},
  author={J{\"u}rgen Braun and Xenofon Baraliakos and Joachim Listing and John Y Davis and D{\'e}sir{\'e}e Mfm van der Heijde and Hildrun Haibel and Mart{\'i}n Rudwaleit and Joachim Sieper},
  journal={Arthritis and rheumatism},
  year={2007},
  volume={57 4},
  pages={639-47}
}
OBJECTIVE Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically and pathologically linked. Anti-tumor necrosis factor (anti-TNF) agents are efficacious in treating AS, but not all are equally effective in treating IBD (Crohn's disease [CD] and ulcerative colitis [UC]). The purpose our study was to analyze the incidence of flares and new onset of IBD in patients with AS treated with anti-TNF agents. METHODS Data from 9 trials, 7 placebo-controlled trials and 2 open… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Similar Papers

Loading similar papers…